Research programme: leishmaniasis DNA vaccine - Mologen/LEISHDNAVAX ConsortiumAlternative Names: MGN 1331; MIDGE-based leishmaniasis DNA vaccine - Mologen/LEISHDNAVAX Consortium
Latest Information Update: 29 Jun 2016
At a glance
- Originator LEISHDNAVAX Consortium; Mologen
- Class DNA vaccines; Leishmaniasis vaccines; Parasitic vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Leishmaniasis